To investigate the change of DNA content and the effect of synthetic phase (S-phase) fraction on hepatocytes and hepatomas, DNA content and S-phase fraction were measured by flow cytometry in human livers and hepatoma tissues. The ploidy status of nontumor parts of resected hepatoma, fetal liver, and focal nodular hyperplasia were diploid, similar to that of the normal liver. Three patterns of DNA ploidy in human hepatoma cells were newly classified, namely, pattern I, diploid tumors; pattern II, aneuploid tumors with single GO/G1 peak; and pattern III, aneuploid tumors with more than one GO/GI peaks. Among the 130 resectable hepatomas measured for DNA ploidy status, 84 (64.6%) were pattern I, 20 (15.4%) pattern II, and 26 (20%) pattern III. Multivariate analyses for those 130 patients who underwent hepatic resection showed that, in addition to tumor size, DNA ploidy was another prognostic factor in predicting overall survival and disease-free survival. Patients with small tumors (< 5 cm) had a significantly higher overall survival rate than those with large tumor (> 5 cm). Patients with pattern III hepatomas had a significantly lower overall survival rate and a higher recurrent rate than did those with pattern I or pattern II tumors. The S-phase fraction was a significant predictor of overall survival rate in patients with pattern II, but not with pattern I, tumors. We conclude that DNA flow-cytometric measurements of ploidy and Sphase fraction are potential important prognostic predictors in patients with resectable hepatomas. (J. Clin. Invest. 1992. 
Introduction
Hepatocellular carcinoma (hepatoma) is a common deadly disease in Asia, especially in Chinese populations. In the Taiwan area, it ranks first in males and third in females as a cause of cancer death (1) . Although some hepatomas with a slow growing property have been reported (2, 3) , the prognosis of hepatomas is very poor. It has been reported that determination of DNA content is helpful in understanding the biological functions and in predicting the prognosis of neoplasm (4) (5) (6) (7) (8) . Previously, using cell cycle analysis, studies on rodent liver carcinogenesis showed a substantial increase in the fraction of diploid hepatocytes, both in preneoplastic liver (9, 10) and tumors (11) (12) (13) . However, ploidy changes in human hepatomas, which have been grouped into diploid and aneuploid status, have been reported to have no correlation with survival of patients with hepatomas who underwent hepatic resection (14, 15) .
Recently, proliferative capacity estimated by fraction ofthe synthesis phase of the cell cycle (S-phase' fraction) in DNA flow analysis has been reported to be useful in predicting the prognosis in node-negative breast cancer ( 16) . In addition, using cell cycle analysis and human hepatoma cell lines, we have found that proliferative capacity correlates well with cells of different differentiation stages (Chiu, J. H., et al., manuscript in preparation). It is, therefore, our interest to measure the ploidy change, estimate the proliferative capacity, and evaluate the clinical importance ofthese measurements in combination with other documented prognostic factors in order to identify patients with resectable hepatomas who may be at high or low risk for tumor recurrence.
In this study, we retrospectively analyzed the DNA ploidy status and proliferative capacity of human liver of benign lesions and 130 resectable hepatomas and used newly classified DNA ploidy pattern to predict biological behavior and survival in patients with resectable hepatomas.
Methods

Patients and specimens
From 1985 to 1990, records of human hepatoma patients in Veterans General Hospital, Taipei, Taiwan, Republic of China, were retrospectively reviewed. 130 patients with surgically resectable hepatomas were eligible for inclusion in this study. Palliative resection, defined as resection with residual tumor proved by any modalities (operative findings, intraoperative ultrasonography or pathology, etc.), were excluded. Information about age of the patient at operation, tumor size, tumor cut margin (the shortest distance between tumor margin and the margin of resected specimen), degree ofliver cirrhosis and infection of hepatitis B virus (HBV) were obtained from well documented records. After operation, the patients were followed up at intervals of 2-4 mo with alphafetoprotein, abdominal ultrasonography, computerized tomography scanning, or angiography as indicated. The hepatoma was considered to be recurrent if any two of these four modalities were interpreted as positive findings.
The tumor and nontumor parts of hepatoma specimens and four focal nodular hyperplasia were obtained from resected specimens. 20-wk and 28-wk fetus livers were obtained according to the regulations of Veterans General Hospital from aborted fetuses, and normal livers from organ donors who died due to car accidents. The fresh samples were kept in liquid nitrogen or a -70'C freezer.
DNA flow cytometry
DNA content was analyzed with fresh, frozen tissue or paraffin-embedded samples with some modification as previously described (17, 18) . In brief, single cell suspensions were prepared from fresh, unfixed surgical specimens or frozen tissue stored at -70'C. They were minced into minute pieces, teased, and filtered. The filtrates were allowed to stand on ice for 5 min. Then, the supernatant was filtered, washed with PBS twice, and resuspended in PBS to a concentration of2-5 x 106 cells/ml.
To the sample was added 0.5 ml (vol/vol) staining solution A (50 4g/ml propidium iodide, no. p-4170; Sigma Chemical Co., St. Louis, MO), 3% polyethyleneglycol 6000 (Art. 807491; Merck, Darmstadt, Germany), 0.1% Triton X-100, 180 U/ml RNase (No. R-5503; Sigma), 4 mM citrate buffer pH 7.2, incubated at 370C for 20 min, followed by the addition of solution B (vol/vol) (50 ,g/ml propidium iodide, 3% polyethyleneglycol 6000, 0.1% Triton X-100, 0.4 M NaCl, pH 7.2). The sample was then stored at 4VC for at least 1 h and filtered before being analyzed using a flow cytometer (Epics Profile; Coulter Electronics, Hialeah, FL) supplemented with an Omnichrome 500 series (150 mW; Ominicon, CA), argon ion laser (25 mW at 488 nm). Red fluorescence was detected through a 610-nm long pass absorbance filter (3802055; Coulter Electronics). All data were analyzed with off-line software (Cytologic; Coulter Electronics). To obtain cell suspensions from paraffin-embedded specimens, 50-,gm sections were cut with a dewaxed with two times 100% xylene, rehydrated in a series ofdescending concentrations of ethanol (3 ml, 10 min, room temperature), washed with distilled water twice and, finally, resuspended in 1 ml of a solution containing 0.5% pepsin (p-6887; Sigma), 0.9% NaCl, pH 1.5. The samples were then placed in a waterbath, 37°C, for 30 min. Approximately 105 cells were present in the sample. The cell suspension was centrifuged and the pellet was resuspended in the staining solution, followed by the procedures as mentioned above.
DNA content was evaluated as presynthetic growth phase (GO/G 1), S-phase, and postsynthetic and mitotic growth phases (G2 + M). The ploidy status was defined as diploid (2N) when GO/Gl peak was superimposed after the addition of human peripheral blood lymphocytes to the samples with a range from 1.9 to 2.1 N, while aneuploid was defined if the discrete GO/Gl peak(s) was/were outside the diploid range (1.9-2.1 N). The DNA ploidy status of human hepatomas could be further classified into three patterns: pattern I, hepatomas with diploid DNA distribution; pattern II, hepatomas with aneuploid DNA content and containing only one prominent GO/G1 peak; and pattern III, hepatomas with aneuploid DNA content and containing > 1 GO/G1 peaks. In this study, the coefficient of variation of the GO/G1 half-peak width of single-peak specimens had to be < 5.0-6.0 for a specimen to be considered interpretable for ploidy status.
Statistical analysis
The data were analyzed using a statistical package (BMDP Statistical Software, Inc., Los Angeles, CA). The primary end points in this study were disease-free survival and overall survival. Patients who died without documented disease recurrence were included in analysis ofoverall survival. Disease-free survival was measured between the date ofopera-DNA content (channel no.) Figure 1 . DNA ploidy distribution in nonmalignant liver tissues, including normal liver (A), nontumor parts of resected hepatoma specimens (B), fetal liver (C), and focal nodular hyperplasia (FNH) (D). The specimens were obtained, treated, and the nuclear DNA contents were analyzed with flow cytometry as described in Methods. Arrows indicate relative DNA content corresponding to diploidy (2N). tion and date of hepatoma recurrence defined by criteria previously mentioned. Curves for overall survival and disease-free survival were calculated according to the method of Kaplan and Meier (19). Cox's partially nonparametric regression model was used to evaluate the predictive power of various combinations ofprognostic factors in a multivariate manner (20) . In tumors of pattern I (diploidy) or pattern II (aneuploidy containing single GO/GI peak), the optimal cutoffs to distinguish DNA content with high S-phase fraction from those with low S-phase fraction were obtained by maximizing the likelihood function with the use of Cox's regression analyses.
Results
DNA pattern ofnonhepatoma livers. Nuclear DNA contents of normal livers, two fetal livers (20 and 28-wk gestation age), four focal nodular hyperplasia, and 78 nontumor parts ofhepatoma specimens were analyzed. They were pathologically proved to have no malignant change. The ploidy distribution of nonhepatoma livers including normal (Fig. 1 A) , nontumor parts of hepatoma specimens resected from hepatoma patients (Fig. 1  B) , fetal livers ( Fig. 1 C) , and focal nodular hyperplasia (Fig. 1  D) were all diploid. DNA pattern of hepatoma tissues. 130 specimens with pathologically proved hepatomas were analyzed with flow cytometry and the nuclear DNA ploidy status ofthese hepatomas was classified into three patterns as described in Methods. Of these 130 specimens, 84 (64.6%) were pattern I (Fig. 2 A) , defined as diploidy (1.9-2.1 N); 20 (15.4%) were pattern II, defined as aneuploidy containing only one GO/G1 peak, either hypoploidy (< 1.9 N) (Fig. 2 B) or hyperploidy (> 2.1 N) ( Fig. 2  C) ; and 26 (20%) were pattern III, defined as aneuploidy containing more than one GO/Gl peaks, either diploidy predominant (Fig. 2 D) , aneuploidy predominant (Fig. 2 E) , or having more than one aneuploid peaks (Fig. 2 F) . Only in pattern I and pattern II specimens could the DNA content be further analyzed with S-phase fraction, since in pattern III tumors the S-phase fractions in the multiple GO/G1 peaks were hardly interpretable. Among these 104 hepatomas, the overall mean percentage of cells in S-phase was 5.70% and a cutoffvalue 6% was used to distinguish high from low S-phase hepatomas. In DNA content (channel number) (Table II) . We examined tumor size of various cutoffs and found that 5 cm was the critical cutoff to yield statistically significant differences (P < 0.05) between large (tumor size > 5 cm) and small (tumor size < 5 cm) hepatomas in overall survival. In addition, DNA ploidy status was another factor in determining the prognosis of patients with resectable hepatomas. In this study, DNA ploidy of hepatoma specimens could be grouped into three patterns (Fig. 2) . Multivariate analyses of these 130 patients showed that there were statistically significant differences in the overall survival rates between patients with pattern I and pattern III tumors (P < 0.003) and between those with pattern II and pattern III tumors (P < 0.05). However, there was no significant difference in overall survival rates between those with pattern I and pattern II hepatomas. The presence of liver cirrhosis or the presence of HBsAg made no statistically significant difference in predicting overall survival rates.
S-phasefraction. Of the 130 specimens that could be analyzed for DNA ploidy status, 104 were also evaluated for S- Actuarial overall survival and disease-free survival according to prognostic groups. Fig. 3 shows the actuarial overall survival for three groups of patients according to ploidy status.
There were statistically significant differences in the overall survival rates between patients with pattern I and pattern III tumors (P < 0.003) and between those with pattern II and pattern III tumors (P < 0.05). The actuarial 5-yr disease-free survival rates (Fig. 4) were all below 10%.
Discussion
In this article, we have used DNA flow cytometry to analyze the DNA content of normal liver, fetal liver, focal nodular hyperplasia, and hepatomas. The results show that measurement of DNA patterns and S-phase fraction have clinical importance in predicting prognosis in patients with resectable hepatomas.
Although having a wider coefficient of variation and more cell debrils, DNA flow cytometry using paraffin blocks still has good correlation between DNA indices with flow cytometry using fresh tissue (21) . It is well accepted that minimized cell debrils and improved quality of DNA histograms can be obtained by using 50-,um or thicker paraffin-embedded sections (21, 22) . Besides, the abnormal DNA distributions have been more easily and more reliably identified in histograms from isolated nuclei, since these give better peak resolution than do the analyses of whole cells ( 15) . Previous studies have speculated on the pattern of DNA ploidy distribution of human hepatomas into two groups, diploid (euploid) and nondiploid (aneuploid), in the order ofwider distribution (14, 15) . In this study, our new system grouped hepatomas into three different patterns, pattern I, pattern II, and pattern III. Pattern I was diploid distribution (2N) as generally accepted; pattern II was aneuploid containing only one prominent GO/GI peak, either hypoploid or hyperploid; and pattern III was aneuploid, containing more than one GO/G1 peaks. Two points about pattern III must be mentioned here. First, was there any relationship between these obvious GO/Gl peaks? Since, in addition to the obvious GO/GI peaks, there usually existed the respective tetraploid (4N) or octoploid (8N) fractions, the prominent GO/Gl peaks seemed to be independent of each other. Second, was the pattern III tumor actually the pattern II tumor contaminated with normal liver parts, yielding a diploid peak in the measurement ofDNA content? It is worthy of mention that the specimens were managed at the time when the tumors were resected and carefully treated to avoid obtaining specimens with necrosis or containing nontumor parts. Besides, a prominent diploid GO/G I peak with an aneuploid GO/G1 peak, and, moreover, two aneuploid peaks, could sometimes be obtained in pattern III tumors. Therefore, contamination of normal hepatocytes to yield a pattern III ploidy distribution, i.e., pattern II (tumor DNA ploidy), mixed with normal hepatocytes (diploid) is not likely.
The DNA pattern, separated into diploid and nondiploid groups, has been reported to correlate with tumor size and age ofpatients but not with the presence of HBsAg or the presence of liver cirrhosis. Furthermore, it was also suggested that there was no significant correlation between DNA pattern and the overall survival rates ofhepatoma patients who underwent hepatic resection (14) . In our study, there was no correlation among DNA pattern and tumor size, age of patients, presence of HBsAg, or presence of liver cirrhosis. Similarly, if the DNA pattern was separated into diploid and nondiploid groups, there was no correlation between DNA pattern and the prognosis of patients who underwent liver resection. However, when the DNA ploidy status is stratified into three patterns, poor prognosis could be observed in patients with pattern III ploidy in terms of overall survival and disease-free survival (Figs. 3  and 4 ). Although most of the patients with hepatomas after resection had tumor recurrence within five years (> 90%), the two-year disease-free survival was 40%, 30%, and 20% in patients with pattern I, II, and III hepatomas, respectively. Also, considering the possibility of selection bias, patients receiving palliative resection (no disease-free survival) were followed up and the mean overall survival times were 12.67±3.74 months and 5.14±1.32 months in those with pattern I and pattern III tumors, respectively (no patients with pattern II hepatomas received palliative resection). The difference between these two groups seemed to be statistically insignificant (P = 0.08). We attributed this to inadequate sample size, and further work on the palliative resection group is ongoing. This result suggests that hepatomas with pattern III ploidy status have more malignant biological behavior than those with pattern I and II ploidy status.
It has been proposed that aneuploid cells may represent distinct tumor cell populations that carry their own stem lines and that the increased tendency toward diploid divisional proliferation may favor the subsequent development of aneuploid subpopulations, a process similar to that described for epithelial or lymphoid tissues (23, 24) . In pattern III tumors, two possibilities can be suggested. First, the tumor cells are of single clonal origin with development of aneuploid subpopulations. Second, the tumor cells originate from more than one stem line. The exact nature of these tumors needs further work at the molecular level.
Although S-phase fraction played a role in the overall survival of patients with pattern II ploidy hepatoma, it had no effect on those with pattern I or diploid tumors. In addition, the lack of statistical significance in overall survival rate between patients with pattern I (diploidy) and pattern II hepatomas suggested that the prognosis of patients with hepatoma seemed to be influenced by other factors, such as tumor size, surgical technique, liver cirrhosis, etc., as previously reported (14), and by tumor size in the present work. Nevertheless, measurement of DNA ploidy and estimation of S-phase fraction in hepatoma patients may be helpful in determining treatment strategies, as demonstrated in treatment of breast cancer (25) .
